In an anticipated turn of events, key drugs widely used across the United States may soon see a price reduction under the Medicare program. If implemented, such a development could result in significant savings for taxpayers, potentially to the tune of billions of dollars, while concurrently impacting the profit margins of large pharmaceutical firms.
Preparations are underway within the U.S. government to disclose a select list of 10 drugs whose prices could be negotiated under the health program specifically designed for the elderly. The list, which constitutes a critical aspect of President Joe Biden’s Inflation Reduction Act, is expected to be released this week. Among the probable candidates for this list are Johnson & Johnson’s blood thinner Xarelto and Eli Lilly & Co.’s diabetes medication Jardiance.
This impending price negotiation represents the first of its kind in U.S history and is already facing staunch opposition from big pharma businesses. However, the benefits for Medicare, and by extension American taxpayers, could be too crucial to overlook.
For more detailed coverage on this development and its potential impacts, please refer to the full article on Bloomberg Law by John Tozzi and Nacha Cattan here.